🇺🇸

US SEC Filing Intelligence

· daily

Dow Jones 30 Stocks SEC Filings — August 28, 2026

The seven filings from Dow 30 constituents reveal a mixed picture for the index. Walmart's Q2 FY27 revenue growth of 5.9% YoY to $187.9B demonstrates robust top-line performance, but a 9.4% decline in net income and a swing to $1.2B in other losses highlight earnings quality concerns. Insider activity at IBM shows contrasting signals: the CEO's $2M phantom stock acquisition signals confidence, while an SVP's $5.76M stock sale raises caution. Boeing's new $364-day credit facility, with rates tied to its credit ratings, suggests ongoing liquidity management amid operational challenges. Procter & Gamble's proxy filings indicate stable governance with a 33% female and 50% racially diverse board, but three shareholder proposals signal governance tensions. Salesforce's insider gifting of 16,000 shares under a 10b5-1 plan is a neutral portfolio adjustment. Overall, the portfolio shows revenue growth but margin pressure, with insider activity providing mixed signals on management conviction.

6 high priority 1 medium 7 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — August 28, 2026

The USA Corporate Distress & Bankruptcy stream for August 28, 2026, reveals a severe wave of Nasdaq and NYSE American non-compliance events, with 14 filings concentrated on going concern warnings, delisting notices, and bankruptcy proceedings. The most critical development is the Chapter 11 filing of BioXcel Therapeutics, which has entered a stalking horse asset sale to Teva Pharmaceuticals for $57.5 million upfront, signaling a distressed exit for a biotech firm. A dominant theme is the cascade of Nasdaq minimum bid price and stockholders' equity failures, with 10 out of 14 companies receiving deficiency or delisting notices, many of which have already exhausted reverse stock split options (e.g., KALA BIO, GeoVax Labs). Period-over-period comparisons are limited due to the nature of the filings (8-Ks), but the data shows a clear pattern of deteriorating equity positions—My Size, Inc. reported equity of $2.347 million (below the $2.5 million threshold), and Oragenics Inc. reported $3.7 million (below $4 million). Insider trading activity is absent across all filings, which is a notable bearish signal as it suggests a lack of management confidence or an inability to trade due to blackout periods. Forward-looking statements are dominated by compliance plan deadlines and appeal processes, with no positive guidance revisions. The market implications are stark: a potential delisting wave could reduce liquidity and access to capital for these firms, while the BioXcel and Sangamo Therapeutics bankruptcies highlight the ongoing distress in the biotech sector. Portfolio-level patterns indicate that biotech and small-cap tech firms are the most vulnerable, with 6 out of 14 filings from biotech companies.

14 high priority 14 total filings
· daily

Global High-Priority Regulatory Events — August 28, 2026

This digest covers 50 filings from August 28, 2026, dominated by a surge in Nasdaq delisting and deficiency notices (11 filings), signaling a severe liquidity and compliance crisis among small-cap biotech and tech firms. The most material event is BioXcel Therapeutics' Chapter 11 bankruptcy filing with a $57.5M stalking horse bid from Teva Pharmaceuticals, creating a high-stakes auction process. In M&A, a major theme is the consolidation of the Indian cement sector via the ACC/Ambuja Cements amalgamation, alongside a significant $1.76B investment by Hero MotoCorp in EV maker Ather Energy. The SPAC sector shows continued stress, with Constellation Acquisition Corp I using its 7th extension and Allegro Merger Corp terminating its merger with SeeQC. A notable positive trend is the strong revenue growth at Cloud Wave Technologies (191% over two years) being acquired by AXISCADES, and Alara Resources Ltd's revenue surging 909% YoY, attracting investment from South West Pinnacle. Insider activity is limited in these filings, but the sheer volume of going concern and delisting risks points to a broad market cleansing event for micro-cap stocks.

50 high priority 50 total filings
· daily

US SEC Filings Daily Market Digest — August 28, 2026

Today's digest reveals a market bifurcated between sectors facing headwinds and those with strong catalysts. The tanker and shipping sector is under pressure, with Hafnia Ltd reporting a 24.8% decline in net income, while the cybersecurity and AI infrastructure spaces show robust growth, exemplified by SentinelOne's 20.5% revenue increase. A significant wave of M&A and restructuring activity is reshaping the landscape, highlighted by BioXcel Therapeutics' Chapter 11 filing and BitGo's acquisition of NYDIG's trading business. Insider activity is mixed, with a notable CEO purchase in the struggling EdTech sector and routine tax-related sales at Marzetti Co. Capital allocation trends show a preference for share buybacks, with News Corp and Southern First Bancshares announcing new programs, while the IPO market shows signs of life with NorthStrive Acquisition Corp's $100M SPAC IPO. The most critical development is the NMPA approval of HUTCHMED's ATLED® for cholangiocarcinoma, a major catalyst for the biotech sector. Portfolio-level patterns indicate a defensive shift in capital allocation towards liquidity and debt management, as seen with Lockheed Martin's new credit facility and JBG SMITH's credit agreement amendment.

24 high priority 26 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — August 28, 2026

The S&P 500 Consumer Discretionary sector saw a quiet session with only three filings, dominated by TJX Companies' strong Q2 FY27 results. TJX reported 5.4% YoY net sales growth to $15.18B and a 22.3% net income surge to $1.52B, driven by improved margins and robust operating cash flow (+53% YoY to $3.35B in H1). The company continued aggressive capital returns ($1.4B buybacks, $1.0B dividends in H1) while increasing capex 21% YoY, signaling confidence in growth. YUM Brands filings were purely administrative—a routine board committee assignment and a phantom stock grant to a new director—with no financial or strategic impact. The key portfolio-level trend is TJX's outperformance in a potentially challenging retail environment, with margin expansion and strong cash generation contrasting with typical sector headwinds. No other companies in the fixed list filed material reports, making TJX the sole actionable focus for investors.

3 high priority 3 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — August 28, 2026

The two filings from Edwards Lifesciences Corp, both dated August 28, 2026, present a mixed but low-materiality picture for this S&P 500 Healthcare component. The first filing (8-K) announces the planned retirement of a senior executive, Donald E. Bobo, Jr., by mid-2027, a routine leadership transition with no immediate financial impact. The second filing (Form 4) reveals an insider sale by a regional vice president, Bruls Annette, of approximately $238,000 worth of stock at $89.98 per share. While the insider sale carries a negative sentiment, its relatively small size and the absence of any broader period-over-period financial trends, guidance changes, or capital allocation actions in these filings limit the depth of portfolio-level insights. The key takeaway is a minor bearish signal from insider activity, offset by a neutral executive transition, with no sector-wide themes emerging from this limited data set.

2 high priority 2 total filings
· daily

US Earnings Financial Results SEC Filings — August 28, 2026

This digest covers 22 enriched SEC filings centered on financial results and earnings, revealing a bifurcated market. Big-cap tech and consumer cyclicals (e.g., Marvell, Autodesk, Gap, Target) posted robust revenue growth and substantial margin expansion, while homebuilders (Hovnanian, Toll Brothers) faced a clear slowdown amid rising rates and inventory adjustments. Several small-cap and pre-revenue life sciences firms showed signs of extended cash burn and operational distress (SeeQC, First Breach), though some, like Anavex, improved cash positions through equity offerings. Insider activity was overall muted, with no major buying or selling across the set, except for strong capital returns via buybacks at Williams-Sonoma and Gap. A dominant theme is 'margin bifurcation,' where 6 out of 17 newly filed companies saw gross margin expand by more than 200 bps, while 3 saw significant compression, making stock selection around cost control a key differentiator. The homebuilding sector is a notable risk area, with two major builders showing double-digit percentage declines in net income.

22 high priority 22 total filings
· daily

US Executive Compensation Proxy SEC Filings — August 28, 2026

This batch of 14 DEF 14A proxy filings reveals a broad market landscape dominated by governance housekeeping and capital structure maneuvers, with a notable cluster of micro-cap companies urgently seeking reverse stock splits to maintain Nasdaq listing compliance. The most critical development across the filings is the prevalence of dilutive proposals: three companies (Bone Biologics, Getty Images, and Profusa) are seeking reverse stock splits, and NN Inc. is doubling its authorized shares, signaling significant future equity needs. Period-over-period data was sparse as these are governance filings, but the insider activity and forward-looking statements provide actionable intelligence. Procter & Gamble stands out as a high-quality governance play with diverse director nominees and a shareholder-friendly stance, while MillerKnoll presents a mixed picture with solid operational progress against a challenging macro backdrop. A pattern of administrative and compliance-driven meetings (Kurv ETF, CBRE Global Real Estate Income Fund, Korea Fund) suggests low materiality for most filings, but the concentrated insider ownership at National Beverage Corp (73.2% CEO ownership) and the urgency of reverse splits at Bone Biologics and Profusa create specific high-conviction signals for risk-aware investors.

14 high priority 14 total filings
· daily

US IPO Pipeline SEC S-1 Filings — August 28, 2026

The August 28, 2026 IPO pipeline is dominated by a wave of new S-1 registrations, including four blank-check companies (Graf Industrial Corp. II, and Talawar Tx Inc. via an S-4 de-SPAC), and diverse operating businesses such as Off The Hook YS (NXB) and Amaero Inc. A major M&A event is the $1.6B all-stock acquisition of Supernus Pharmaceuticals by Indivior, creating a diversified neuroscience leader (Indivior/Supernus S-4). Financially, Off The Hook YS shows strong revenue growth (+21% YoY) but a sharp swing to net losses, with operating expenses surging 180% in H1 2026. Several smaller biotech issuers (Sunshine Biopharma, Adaptin Bio) face existential risks related to Nasdaq compliance and cash burn. The pipeline illustrates a bifurcated market: high-growth companies entering public markets despite deteriorating profitability, while distressed issuers attempt to access capital to survive. Key trends include increasing use of complex equity structures (multiple share classes, warrants) and a continued reliance on SPACs for going public.

11 high priority 11 total filings
· daily

US SEC Trading Suspension Halt Orders — August 28, 2026

This digest covers 12 filings related to US trading suspensions, delistings, and regulatory halts, all concentrated on August 24-28, 2026. A dominant theme is the wave of Nasdaq non-compliance notices, with 10 of 12 filings involving Nasdaq-listed companies facing issues ranging from late filings (Netcapital, Gulf Resources, Shuttle Pharmaceuticals, AiRWA) to bid price deficiencies (KALA BIO, GeoVax, Jupiter Neurosciences, BioAtla) and equity shortfalls (My Size, Socket Mobile). Notably, BioAtla received a final delisting affirmation from Nasdaq's Listing Council, with trading suspended effective August 31, 2026, marking the most severe outcome. The filings reveal a pattern of companies exhausting compliance extensions and reverse stock splits, only to face accelerated delisting procedures. Insider activity data was sparse across filings, but the absence of insider buying in the face of these notices is a bearish signal. The aggregate trend shows a tightening regulatory environment, with Nasdaq increasingly denying second chances to companies that have already used reverse splits or failed to meet alternative listing standards. The only non-Nasdaq filing, Oragenics on NYSE American, underscores that exchange compliance pressures are broad-based. Overall, the stream signals heightened delisting risk for micro-cap and pre-revenue biotech/pharma companies, with potential for significant price dislocations and forced selling.

12 high priority 12 total filings
· daily

US Executive Officer Management Changes SEC — August 28, 2026

The 29 filings reveal a day of significant executive and director changes across diverse sectors, with a notable concentration of CFO transitions and departures. Key themes include a wave of CFO changes at Pinterest, Lindsay Corp, and Vyome Holdings, alongside several director resignations and board appointments. While most changes are routine, Getty Images stands out with a highly material $92.3 million adverse judgment and a director resignation, creating a clear risk flag. Insider activity is limited, but retention bonuses at Latch and Pro-Dex suggest efforts to stabilize leadership. Period-over-period comparisons are sparse in these filings, but the capital allocation data from Steele Bancorp shows a significant increase in executive retirement benefits, signaling a focus on long-term retention. The overall sentiment is neutral, with isolated positive signals from board appointments at IonQ and Altria, and negative signals from Getty Images and the CFO departures at Pinterest and Outset Medical.

29 high priority 29 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — August 28, 2026

The USA Bankruptcy & Insolvency stream for August 28, 2026, reveals a concentrated wave of biopharma Chapter 11 filings, with both BioXcel Therapeutics and Sangamo Therapeutics entering court-supervised restructuring to monetize core assets via stalking horse auctions. BioXcel's deal with Teva Pharmaceuticals for $57.5M upfront plus up to $87.5M in milestones provides a floor valuation, while Sangamo's sale of its Fabry gene therapy asset (ST-920) to PTC Therapeutics lacks disclosed upfront consideration, signaling potentially distressed pricing. Both filings underscore a sector theme of cash-constrained biotechs liquidating pipeline assets to repay creditors, with no revenue growth or insider buying to offset negative sentiment. The absence of period-over-period comparisons or forward guidance in these initial filings limits trend analysis, but the materiality scores (10/10 and 9/10) highlight high-impact events for investors monitoring bankruptcy recoveries and distressed asset valuations.

2 high priority 2 total filings
· daily

USA Insider Trading Pulse — August 28, 2026

The August 28, 2026, insider trading pulse reveals a market with a distinct bifurcation: aggressive insider buying in select value-oriented and small-cap names (American Assets Trust, Matador Resources, 17 Education) contrasts sharply with significant, often 10b5-1 plan-driven, selling by senior executives at large-cap technology and industrial firms (IBM, Alcoa, Intuit). A dominant theme is the high volume of routine, non-actionable filings—director stock awards, tax-withholding transactions, and unparseable EDGAR documents—which constitute the majority of the 50 filings. However, the actionable signals are concentrated in a few high-conviction insider purchases, notably the Executive Chairman of American Assets Trust deploying $2.26M, and a notable cluster of selling activity at Lightbridge Corp and Caesars Entertainment. The data suggests a cautious posture among insiders at larger, more liquid names, while signaling potential deep value or turnaround conviction in smaller, out-of-favor sectors. No significant period-over-period financial trends or forward-looking guidance changes were present in the filings, making the insider transaction patterns the primary source of intelligence.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — August 28, 2026

The US M&A landscape is bifurcated: two new SPAC IPOs (NorthStrive, Rainier) signal continued appetite for blank-check vehicles, but three existing SPACs (Andretti, Constellation, Allegro) are struggling to close deals, with Allegro's merger termination and Constellation's seventh extension highlighting execution risk. A major strategic acquisition closed in the critical minerals space (Energy Fuels buying ASM for $243M), while Intrusion Inc. secured emergency debt financing at a 7.7% discount, suggesting financial distress. Period-over-period data reveals a clear pattern of SPACs burning cash with no revenue, while Energy Fuels stands out as the only filing with a completed, value-creating transaction. Insider activity is absent across all filings, but forward-looking data points to a catalyst-rich September with Andretti's shareholder vote and Constellation's next deadline. The sector theme is a tale of two markets: capital is flowing into new SPACs, but existing ones face a credibility crisis with investors demanding deals or liquidation.

7 high priority 7 total filings
· monthly

US Pre-Market SEC Filings Roundup — August 28, 2026

Overnight filings reveal a bifurcated market landscape with significant distress signals in the healthcare and technology sectors, offset by strategic capital deployment in infrastructure and energy. The most critical development is BioXcel Therapeutics' Chapter 11 filing with a stalking horse bid from Teva Pharmaceuticals, highlighting the high-risk nature of biotech. Lumentum Holdings saw a coordinated wave of insider selling by multiple top executives, including the CEO and CFO, totaling over $6.7 million, a bearish signal for the optical components sector. Conversely, a major strategic investment in VNET Group by a consortium backed by CATL signals a bullish long-term bet on Chinese data center infrastructure. Hafnia Ltd reported a 24.8% decline in net income, reflecting a challenging tanker market, while Netcapital faces a Nasdaq delisting risk due to filing delays. The overall theme is one of caution, with capital being redeployed from distressed assets into strategic long-term plays, and insider activity suggesting management concern in specific names.

36 high priority 14 medium 50 total filings
· daily

New Drug Approvals (Original) — August 27, 2026

The August 27, 2026 FDA approval stream delivered three biosimilar approvals (SOCORRO N1's NITROGLYCERIN, ZYDUS LIFESCIENCES' RIFABUTIN, and LAURUS' TICAGRELOR), with zero NMEs, zero label expansions, and zero bullish signals. The period is characterized by low commercial materiality, as all three approvals are for established generic/biosimilar molecules with NOT_DISCLOSED peak sales estimates and no disclosed exclusivity or pricing power. No dominant therapeutic area theme emerges, as the approvals span cardiovascular (NITROGLYCERIN, TICAGRELOR) and anti-infective (RIFABUTIN) categories. The highest-conviction signal is the neutral entry of LAURUS into the TICAGRELOR market, which could pressure originator AstraZeneca's BRILINTA franchise over time, though the lack of disclosed market position limits conviction. Key risk is the absence of NME or breakthrough approvals, signaling a dry period for high-value catalysts and potential pipeline weakness across the sector.

3 total filings
· daily

VA Healthcare & Services Contracts — August 27, 2026

This digest covers a single $136.95M civilian contract awarded by the Department of Veterans Affairs to UnitedHealth Group's OptumRx subsidiary for pharmacy benefit management services. The contract is a firm-fixed-price delivery order with a short four-month performance period, generating a high monthly run rate of ~$34M. While the award validates OptumRx's competitive position in the stable VA market, the short duration and competitive bidding environment introduce uncertainty regarding revenue recurrence. The neutral signal strength reflects balanced risk-reward, with no bullish or bearish catalysts identified in this isolated award.

1 total filings
· daily

New Federal Contractors — August 27, 2026

This digest of five new federal contracts, totaling $662.4M in obligations, reveals a predominantly civilian-focused procurement environment, with only one defense-related award (HII Mission Technologies Corp at $157.3M). The highest-conviction signal is the bullish, cost-plus award fee contract for Noridian Healthcare Solutions, LLC ($116.8M initial obligation, up to $573.6M total) from CMS for Medicare Fee-For-Service support, offering stable, low-risk revenue. A key risk is the short-duration, firm-fixed-price PBM contract for OptumRx ($136.9M over four months), which shifts cost risk to the contractor and lacks long-term visibility. The digest highlights a trend toward large, recurring civilian agency contracts in healthcare and social services, with defense exposure limited to a single Navy engineering support award.

5 total filings
· daily

Significant Contract Modifications ($10M+) — August 27, 2026

This digest covers five government contract actions totaling $662.4 million in obligations, with only one defense-related award (HII Mission Technologies at $157.3M) and four civilian contracts. The dominant theme is civilian agency healthcare and IT services, led by Noridian Healthcare Solutions' $116.8M CMS contract (potential $573.6M over 10 years) and OptumRx's $136.95M VA pharmacy benefit management order. The highest-conviction signal is HII's Navy engineering support contract, which provides a five-year recurring revenue stream and validates Huntington Ingalls' diversification into services. A key risk is the expired Business Integra NASA IT contract ($149.3M obligated), which creates a revenue gap for that contractor and signals potential re-compete vulnerability.

5 total filings